Kangzhi pharmaceutical co., LTD. And hengzhuo technology co., LTD
4, 2016, in guangzhou. The present domestic only one in the children's medicine - Kang Zhi pharmaceutical listed company (stock code: 300086) and Beijing heng zhuo technology holdings co., LTD., held a signing ceremony, officially reached a strategic partnership, the two sides hope through love benefit cochlear product promotion, to promote the development of cochlear technology in the domestic market and progress. Mr. Hong jiangyou, chairman of kangzhi pharmaceutical, Mr. Wang Yang, chairman and CEO of hengzhuo technology, and Mr. Lin guochun, vice President of yuexiu industrial investment fund and other guests attended the signing ceremony.
Cochlear implant technology is an international high-tech means for the treatment of severe hearing impairment. There are about 28 million people with hearing impairment in China, and about 50,000 people aged 0-6 with severe hearing impairment are newly added every year. Most of them can be restored by cochlear implant technology. The existing cochlear implant products are expensive and monopolized by imported brands, so the domestic market is in urgent need of domestic products with moderate prices to achieve import substitution.
Constant zhuo the science and technology is the world's few research and development and production of cochlear ability of companies, is one of the three domestic cochlear enterprise, its love benefit cochlear significant product advantage, have the most simple minimum size, structure, the characteristics of the minimum operation difficulty, in the cochlear implant patents have been granted the CFDA third class medical device registration certificate, the treatment effect is reached leading level at home and abroad.
Kangzhi pharmaceutical has always been focusing on the field of children's health. As the strategic partner of hengzhuo technology, kangzhi pharmaceutical has increased its capital to become a shareholder of hengzhuo technology, hoping to benefit more hearing-impaired children with the technical advantages of hengzhuo technology in the field of cochlear implant technology. Regarding the strategic cooperation plan of the two sides, hong jiangyou, chairman of kangzhi pharmaceutical, said, "this significant cooperation is the exploratory layout of kangzhi pharmaceutical in the field of medical devices. In the New Year, kangzhi pharmaceutical will give full play to its advantages in resources and traditional channels, join hands with hengzhuo technology to achieve a win-win situation in market development, product promotion, terminal construction and other aspects, and bring Gospel to more hearing-impaired people, especially hearing-impaired children through aiyisheng cochlear implant technology.
Wang Yang, chairman and CEO of hengzhuo technology, said, "kangzhi pharmaceutical has been deeply engaged in the children's medicine market for many years and is the company with the most complete series of children's medicine products at present. The choice of cochlear implant market with high technical barriers by kangzhi pharmaceutical this time reflects its attention to medical technology and optimistic prospect of high-end medical market. Hengzhuo technology will rely on kangzhi's business layout in the domestic pharmaceutical market to improve its market share and further strengthen its brand influence and marketing ability.
In the context of the overall slowdown of the pharmaceutical manufacturing industry, medical devices and medical services have undoubtedly become important strategies in the process of enterprise transformation and upgrading. This entry into the high-end medical device market indicates another important deployment of kangzhi pharmaceutical in the field of children's health. It is understood that kangzhi pharmaceutical has started the strategy of children's health in an all-round way. In the future, it will continue to accelerate the expansion from children's medicine to other related fields of children's health.